search
Back to results

Starter Kit Study in Insulin naïve Patients

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 2
Locations
Denmark
Study Type
Interventional
Intervention
Starter Kit Algorithm
Sponsored by
Signe Schmidt
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Type 2 diabetes
  • Age 18-75 years
  • HbA1c 53-86 mmol/mol (7.0-10.0%)
  • BMI 20-40 kg/m2
  • Insulin-naïve
  • Willingness to use CGM consistently during the study period and send/receive data and dose advice to/from HCP via a mobile phone
  • Signed informed consent prior to any study procedures

Exclusion Criteria:

  • Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods
  • Active proliferative retinopathy
  • Mean blood glucose > 15 mmol/l the week prior to screening
  • Blood glucose > 20 mmol/l on the screening day
  • Non-fasting ketones > 0,5 mmol/l on the screening day
  • Use of sulfonylurea within 14 days prior to or during the study period
  • Change in other antidiabetic medicine than basal insulin during the study period
  • Use of corticosteroids within 30 days prior to or during the study period
  • Marked change in lifestyle within 30 days prior to or during the study period as assessed by the investigator
  • People with type 2 diabetes that suffer from conditions which make tight diabetes control undesirable, e.g. severe cardiovascular disease, according to the investigator
  • Other concomitant medical or psychological condition that according to the investigator's assessment makes the patient unsuitable for study participation
  • Overall treatment

Sites / Locations

  • Hvidovre University Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

The Starter Kit Algorithm

Arm Description

Basal insulin initiation and titration using the Starter Kit Algorithm at two weeks, followed by standard of care titration during the following the next 10 weeks (maximum), or until optimal daily dose is considered identified.

Outcomes

Primary Outcome Measures

Accuracy of estimate 1
Accuracy of the estimated optimal daily dose (calculated by the Starter Kit algorithm based on continuous glucose monitoring (CGM) data collected during day 1-14) compared with the observed optimal daily dose in percentage deviation. In this context, optimal daily dose is the dose considered to keep fasting glucose levels below 6 mmol/L.
Accuracy of estimate 2
The number of estimated optimal daily doses by the Starter Kit Algorithm at two weeks that fall within a patient specific confidence interval. The confidence interval is determined using the Starter Kit Algorithm at the end of study, one interval for each patient. Upper boundary: the optimal daily dose estimated to bring lowest hour of CGM values within a day to 4.0 mmol/L Lower boundary: the optimal daily dose estimated to bring lowest hour of CGM values within a day to 6.0 mmol/L

Secondary Outcome Measures

Accuracy of estimate 3
Accuracy of the estimated optimal daily dose (calculated based on self-monitored blood glucose data collected during day 1-14) compared with the observed optimal daily dose.
Number of patients in glucose target
Number of participants in target at end of study
Algorithm deviations
Number of titration algorithm deviations due to risk of hypoglycemia (based on evaluation of CGM data)
Quality of treatment 1
Qualitative assessment by the investigator of participants who do not reach the observed optimal daily dose within 12 weeks: Frequency of participants who are in need of additional basal insulin to achieve the target blood glucose.
Quality of treatment 2
Qualitative assessment by the investigator of participants who do not reach the observed optimal daily dose within 12 weeks: Frequency of participants who are in need of additional drugs to achieve the target blood glucose.
Number of self-monitored blood glucose values ≤3.9 mmol/L
Number of self-monitored blood glucose values ≤3.9 mmol/L
Number of self-monitored blood glucose values ≤3.0 mmol/L
Number of self-monitored blood glucose values ≤3.0 mmol/L
Severe hypoglycemia
Number of severe hypoglycemic events (defined as severe cognitive impairment requiring external assistance for recovery).
Time spent in hypoglycemia
Time spent in hypoglycemia (<3.9 mmol/L) assessed by CGM during the first four study days (days without insulin) and the last four study days (days with optimal daily insulin dose).
Time spent in hyperglycemia
Time spent in hyperglycemia (>10 mmol/L) assessed by CGM during the first four study days (days without insulin) and the last four study days (days with optimal daily insulin dose).
Time spent in normoglycemia
Time spent in normoglycemia (3.9-10.0 mmol/L) assessed by CGM during the first four study days (days without insulin) and the last four study days (days with optimal daily insulin dose).

Full Information

First Posted
September 6, 2017
Last Updated
February 10, 2020
Sponsor
Signe Schmidt
Collaborators
Technical University of Denmark, Novo Nordisk A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT03365180
Brief Title
Starter Kit Study in Insulin naïve Patients
Official Title
Starter Kit Study in Insulin naïve Patients With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
February 2020
Overall Recruitment Status
Completed
Study Start Date
January 3, 2018 (Actual)
Primary Completion Date
November 1, 2019 (Actual)
Study Completion Date
January 15, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Signe Schmidt
Collaborators
Technical University of Denmark, Novo Nordisk A/S

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The concept consists of an initial period (two weeks) of intensive data capture by use of continuous glucose monitoring (CGM) during basal insulin initiation, followed by a second period (variable duration) of basal insulin titration guided by self monitored blood glucose. Data captured during the first period are used as input to an algorithm that estimates the optimal daily dose for the individual patient. The estimated optimal daily dose is used to guide the titration of the basal insulin during the second period. The goal is to safely and successfully achieve blood glucose targets. The concept is based on the use of basal insulin degludec (Tresiba, Novo Nordisk A/S).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
8 (Actual)

8. Arms, Groups, and Interventions

Arm Title
The Starter Kit Algorithm
Arm Type
Experimental
Arm Description
Basal insulin initiation and titration using the Starter Kit Algorithm at two weeks, followed by standard of care titration during the following the next 10 weeks (maximum), or until optimal daily dose is considered identified.
Intervention Type
Device
Intervention Name(s)
Starter Kit Algorithm
Intervention Description
Long acting insulin titration to target
Primary Outcome Measure Information:
Title
Accuracy of estimate 1
Description
Accuracy of the estimated optimal daily dose (calculated by the Starter Kit algorithm based on continuous glucose monitoring (CGM) data collected during day 1-14) compared with the observed optimal daily dose in percentage deviation. In this context, optimal daily dose is the dose considered to keep fasting glucose levels below 6 mmol/L.
Time Frame
through study completion, 12 weeks
Title
Accuracy of estimate 2
Description
The number of estimated optimal daily doses by the Starter Kit Algorithm at two weeks that fall within a patient specific confidence interval. The confidence interval is determined using the Starter Kit Algorithm at the end of study, one interval for each patient. Upper boundary: the optimal daily dose estimated to bring lowest hour of CGM values within a day to 4.0 mmol/L Lower boundary: the optimal daily dose estimated to bring lowest hour of CGM values within a day to 6.0 mmol/L
Time Frame
through study completion, 12 weeks
Secondary Outcome Measure Information:
Title
Accuracy of estimate 3
Description
Accuracy of the estimated optimal daily dose (calculated based on self-monitored blood glucose data collected during day 1-14) compared with the observed optimal daily dose.
Time Frame
through study completion, 12 weeks
Title
Number of patients in glucose target
Description
Number of participants in target at end of study
Time Frame
through study completion, 12 weeks
Title
Algorithm deviations
Description
Number of titration algorithm deviations due to risk of hypoglycemia (based on evaluation of CGM data)
Time Frame
12 weeks (total duration of study)
Title
Quality of treatment 1
Description
Qualitative assessment by the investigator of participants who do not reach the observed optimal daily dose within 12 weeks: Frequency of participants who are in need of additional basal insulin to achieve the target blood glucose.
Time Frame
through study completion, 12 weeks
Title
Quality of treatment 2
Description
Qualitative assessment by the investigator of participants who do not reach the observed optimal daily dose within 12 weeks: Frequency of participants who are in need of additional drugs to achieve the target blood glucose.
Time Frame
through study completion, 12 weeks
Title
Number of self-monitored blood glucose values ≤3.9 mmol/L
Description
Number of self-monitored blood glucose values ≤3.9 mmol/L
Time Frame
12 weeks (total duration of study)
Title
Number of self-monitored blood glucose values ≤3.0 mmol/L
Description
Number of self-monitored blood glucose values ≤3.0 mmol/L
Time Frame
12 weeks (total duration of study)
Title
Severe hypoglycemia
Description
Number of severe hypoglycemic events (defined as severe cognitive impairment requiring external assistance for recovery).
Time Frame
12 weeks (total duration of study)
Title
Time spent in hypoglycemia
Description
Time spent in hypoglycemia (<3.9 mmol/L) assessed by CGM during the first four study days (days without insulin) and the last four study days (days with optimal daily insulin dose).
Time Frame
8 days (first four and last four days of study)
Title
Time spent in hyperglycemia
Description
Time spent in hyperglycemia (>10 mmol/L) assessed by CGM during the first four study days (days without insulin) and the last four study days (days with optimal daily insulin dose).
Time Frame
8 days (first four and last four days of study)
Title
Time spent in normoglycemia
Description
Time spent in normoglycemia (3.9-10.0 mmol/L) assessed by CGM during the first four study days (days without insulin) and the last four study days (days with optimal daily insulin dose).
Time Frame
8 days (first four and last four days of study)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Type 2 diabetes Age 18-75 years HbA1c 53-86 mmol/mol (7.0-10.0%) BMI 20-40 kg/m2 Insulin-naïve Willingness to use CGM consistently during the study period and send/receive data and dose advice to/from HCP via a mobile phone Signed informed consent prior to any study procedures Exclusion Criteria: Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods Active proliferative retinopathy Mean blood glucose > 15 mmol/l the week prior to screening Blood glucose > 20 mmol/l on the screening day Non-fasting ketones > 0,5 mmol/l on the screening day Use of sulfonylurea within 14 days prior to or during the study period Change in other antidiabetic medicine than basal insulin during the study period Use of corticosteroids within 30 days prior to or during the study period Marked change in lifestyle within 30 days prior to or during the study period as assessed by the investigator People with type 2 diabetes that suffer from conditions which make tight diabetes control undesirable, e.g. severe cardiovascular disease, according to the investigator Other concomitant medical or psychological condition that according to the investigator's assessment makes the patient unsuitable for study participation Overall treatment
Facility Information:
Facility Name
Hvidovre University Hospital
City
Hvidovre
ZIP/Postal Code
2650
Country
Denmark

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
31941361
Citation
Aradottir TB, Bengtsson H, Jensen ML, Poulsen NK, Boiroux D, Jensen LL, Schmidt S, Norgaard K. Feasibility of a New Approach to Initiate Insulin in Type 2 Diabetes. J Diabetes Sci Technol. 2021 Mar;15(2):339-345. doi: 10.1177/1932296819900240. Epub 2020 Jan 15.
Results Reference
result

Learn more about this trial

Starter Kit Study in Insulin naïve Patients

We'll reach out to this number within 24 hrs